Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

“We are thrilled to reach this crucial milestone in our clinical program”, said Dr. Hermann Luebbert, CEO and Chairman of Biofrontera Inc. “The results of this Phase 2b study show promising reductions ...
Nasdaq

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical ...

WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), received ...
Healio

M-PDT efficacy similar to isotretinoin in acne vulgaris

Please provide your email address to receive an email when new articles are posted on . M-PDT showed similar efficacy rates compared with isotretinoin with fewer adverse events. A faster onset of ...
Healio

Encapsulated benzoyl peroxide, tretinoin may improve severe acne vulgaris

Please provide your email address to receive an email when new articles are posted on . A combination of microencapsulated benzoyl peroxide and microencapsulated tretinoin significantly improved ...
Seeking Alpha

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...
Nasdaq

Ascletis Reports Positive Phase 3 Safety Results Of Denifanstat In Moderate-to-Severe Acne

(RTTNews) - Ascletis Pharma Inc. (HKEX: 1672) today announced positive topline results from its Phase 3 study for Denifanstat, a once-daily oral fatty acid synthase (FASN) inhibitor for ...
Morningstar

Almirall Announces the Approval of Seysara® in China for the Treatment of Moderate-to-Severe Acne

Almirall, S.A. (ALM)a global pharmaceutical company dedicated to medical dermatology announced today that China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline ...
Business Insider

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More ...
Seeking Alpha

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology ...

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis ...